NEW YORK (GenomeWeb News) – Fluidigm reported after the close of market Wednesday that its first-quarter revenues jumped 33 percent year over year as the company was essentially cash flow neutral for the first time in any quarter in its history.

The South San Francisco-based firm netted total revenues of $14.5 million for the three-month period ended March 31, compared to $10.9 million in the first quarter of 2012. It edged out the consensus Wall Street estimate of $14.3 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.